Home / Technology & Devices (page 4)

Technology & Devices

QIAGEN Acquires N-of-One, Expanding Its Clinical Bioinformatics Capabilities in Molecular Oncology Decision Support

Redwood City, California, and Hilden, Germany, January 7, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today it has entered into an agreement to acquire N-of-One, Inc., a privately-held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data. The addition of N-of-One …

Read More »

C4 Therapeutics Announces Transformation of Strategic Collaboration to Discover and Develop Degrader-Based Medicines with Roche

WATERTOWN, Mass.–(BUSINESS WIRE)–C4 Therapeutics (C4T) announced the transformation of its ongoing research and development partnership with Roche focusing on new cancer treatments based on C4T’s targeted protein degradation technology. “We are excited to see our partnership with Roche evolve and further accelerate our efforts to bring degrader-based medicines into the clinic,” …

Read More »

Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets

CAMBRIDGE, Mass. and WALTHAM, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) — Biogen Inc (Nasdaq: BIIB) and Skyhawk Therapeutics, Inc. (Skyhawk) today announced a strategic collaboration in which the companies will leverage Skyhawk’s SkySTAR™ technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases. Biogen will have the …

Read More »

Veracyte and Johnson & Johnson Innovation to Collaborate for Novel Diagnostic Tests to Detect Lung Cancer at its Earliest Stages

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (“Veracyte”) (Nasdaq: VCYT) announced today that it has entered into a long-term strategic collaboration with Johnson & Johnson Innovation LLC* and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest …

Read More »

FDA Approves Myriad’s BRACAnalysis CDx as Companion Diagnostic for Lynparza in Patients with Advanced-Stage, BRCA-Mutated Ovarian Cancer

SALT LAKE CITY, Dec. 19, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® to be used by healthcare professionals to identify patients with advanced ovarian cancer who have a germline BRCAmutation …

Read More »

X-Chem Enters Strategic Collaboration with Bristol-Myers Squibb

WALTHAM, Mass.–(BUSINESS WIRE)–X-Chem, Inc., a privately held biotechnology company focused on applying its industry-leading DNA-encoded (DEX™) library drug discovery engine to the generation of novel small molecule therapeutics, today announced the signing of a broad strategic drug discovery collaboration with Bristol-Myers Squibb. The collaboration will enable the discovery of novel lead …

Read More »

Amgen And Molecular Partners Announce Strategic Collaboration In Immuno-Oncology

THOUSAND OAKS, Calif. and ZURICH-SCHLIEREN, Switzerland, Dec. 18, 2018 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Molecular Partners AG(SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin®therapeutics, today announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x 4-1BB). MP0310 is a preclinical …

Read More »

Guardant Health Partners with AstraZeneca to Develop Blood-Based Companion Diagnostic Tests for Tagrisso and Imfinzi

REDWOOD CITY, Calif., Dec. 13, 2018 (GLOBE NEWSWIRE) — Guardant Health (Nasdaq: GH) announced a multi-year agreement with AstraZeneca (NYSE: AZN) to develop blood-based companion diagnostic (CDx) tests supporting the commercialization of AstraZeneca’s oncology portfolio based on Guardant’s industry-leading comprehensive liquid biopsy platform. Under the terms of the agreement, Guardant …

Read More »

Dragonfly Therapeutics Announces Celgene In-license of First Two TriNKET Immunotherapy Drug Candidates

WALTHAM, Mass., Dec. 13, 2018 /PRNewswire/ — Dragonfly Therapeutics, Inc. (“Dragonfly” or the “Company”), today announced it has licensed two TriNKET™ immunotherapy drug candidates to Celgene Corporation and its affiliates (“Celgene”) for $12m each plus prospective milestones and royalties.  The licenses represent the first two of four hematological cancer targets …

Read More »

Roche to Develop Companion Diagnostic Test to Identify Patients Eligible for Anti-PD-1 Therapy Based on Biomarker Expression

TUCSON, Ariz., Dec. 11, 2018 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it entered into a collaboration with Merck (known as MSD outside the United States and Canada) to develop a companion diagnostic test to identify patients eligible for anti-PD-1 therapy based on the status of …

Read More »